Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00273325 · ClinicalTrials.gov registry record

Immunogenicity of PCV-7 Vaccine in VLBW Infants

A clinical trial, sponsored by NICHD Neonatal Research Network.

Completed
Registry status
368
Enrollment target

NCT00273325: Completed study, sponsored by NICHD Neonatal Research Network.

NCT00273325 is a clinical trial that has completed, run by NICHD Neonatal Research Network. The registered enrollment target is 368 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00273325 has completed, sponsored by NICHD Neonatal Research Network.

COMPLETED
Registry status
368 participants
Enrollment target

Study Summary

Premature infants are at a high risk for pneumonia. The PCV-7 vaccine effectively prevents the invasive disease from Streptococcus pneumoniae in full-term infants, but was not thoroughly studied in premature infants. This study evaluated the effectiveness and safety of the vaccine given in routine practice to very low birth weight infants, looking at blood antibody levels 4-6 weeks after the final vaccine dose, and adverse events, survival, infections, and neurodevelopmental outcomes at 18-22 months corrected age.

Trial Details

FieldValue
Enrollment Target 368 participants
Start Date 2004-07
Est. Completion 2009-03
NICHD Neonatal Research Network

61 total trials

What the finished NCT00273325 record still lists

NCT00273325 is an observational study that tracks outcomes without assigning an intervention. The registered 368 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00273325 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00273325 about?

NCT00273325 is a clinical study titled "Immunogenicity of PCV-7 Vaccine in VLBW Infants". Premature infants are at a high risk for pneumonia. The PCV-7 vaccine effectively prevents the invasive disease from Streptococcus pneumoniae in full-term infants, but was not thoroughly studied in premature infants. This study evaluated the effectiveness and safety of the vaccine given in routine p...

What is the current status of trial NCT00273325?

This trial is currently completed. The enrollment target is 368 participants. The study started on 2004-07. Estimated completion is 2009-03.

Who is sponsoring clinical trial NCT00273325?

This trial is sponsored by NICHD Neonatal Research Network, which has 61 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04675476 · 368 participants · NA

    A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening

  • NCT05215353 · 368 participants · Phase 4

    A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors

  • NCT06182397 · 368 participants · NA

    Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease

  • NCT06629610 · 368 participants · NA

    Diet and Active Lifestyle - Yuuyaraq (The Yup'ik Way of Life)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00273325, the US trial registry maintained by the National Library of Medicine. NCT00273325 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.